Fluent

Fluent Net Debt / EBITDA

Delisted

The Net Debt to EBITDA of Fluent (TIUM.U.CN) as of Nov 5, 2026 is 2.91. In the previous year, Net Debt to EBITDA was 4.43 — a change of -34.39% (lower).

Net Debt / EBITDA

2.91

YoY

-34.39%

Last updated:

Net Debt to EBITDA of Fluent is 2023 2.91 . Net Debt to EBITDA of Fluent was 2022 4.43 . It decreases by -34.39% lower compared to the previous year.

The Fluent Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2019
-1.86 USD
Jan 1, 2020
-3.60 USD
Jan 1, 2021
-7.54 USD
Jan 1, 2022
4.43 USD
Jan 1, 2023
2.91 USD
The Fluent Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
2.91-34.39%
4.43-158.84%
-7.54+109.45%
-3.60+93.59%
-1.86—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluent Stock analysis

What does Fluent do? Fluent Corp operates under the private label Fluent, selling medical cannabis products in Florida, Texas, and Pennsylvania. The company's products include oral drops, capsules, suppositories, topicals, syringes, dried flower, pre-rolls, cartridges, edibles, and accessories. Subsidiaries such as Cansortium Holdings LLC and Cansortium Florida, LLC handle production and sales, while Fluent Servicing, LLC manages servicing aspects. The company's revenue comes from direct sales of medical cannabis products through its licensed operations in multiple states. Fluent Corp's target customers are patients seeking medical cannabis treatments, with products tailored to various consumption methods. The company leverages its subsidiaries to maintain compliance and expand its market reach across different states. Sales are conducted through licensed dispensaries and medical cannabis programs, focusing on the healthcare segment of the cannabis industry. The business model relies on the production and sale of medical cannabis under the private label Fluent, utilizing subsidiaries to manage state-specific operations. Products are distributed through established medical cannabis channels, with no mention of additional revenue streams beyond product sales. The company's focus remains on the medical cannabis market, serving patients in Florida, Texas, and Pennsylvania. Fluent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluent stock

Net Debt to EBITDA of Fluent is 2.91 in 2023.

Net Debt to EBITDA of Fluent changed from 4.43 to 2.91, representing a -34.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Fluent since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Fluent with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Fluent

All Key Metrics — Fluent